Rachel Tang

University of California, Los Angeles — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

10h-index527citations29works2.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Tyrosine Phosphatases(11), Nanoplatforms for cancer theranostics(10), Calcium signaling and nucleotide metabolism(10), Photodynamic Therapy Research Studies(9), Ion Channels and Receptors(6)

Publications29 total

Resilient high-temperature reverse osmosis desalination membranes
Science Advances·2026Open Access
Embossing-Free Permeate Carrier for Ultrahigh Pressure Reverse Osmosis
Environmental Science & Technology·2025
Polymethoxyflavones from Kaempferia parviflora stimulate melanogenesis by blocking the TPC2 channel
Scientific Reports·2025Open Access
TRPML2 channel modulation by PI(3,5)P₂ and small-molecule agonists controls endosomal vesicle dynamics
Biomedicine & Pharmacotherapy·2025Open Access
101 Parenteral Bridging Practices and Outcomes in Patients on Warfarin for Mechanical Heart Valves and Venous Thromboembolism
Research and Practice in Thrombosis and Haemostasis·2025Open Access
TPC2: From Blond Hair to Melanoma?
Cancers·2024· 2 citedOpen Access
Rab7a is an enhancer of TPC2 activity regulating melanoma progression through modulation of the GSK3β/β-Catenin/MITF-axis
Nature Communications·2024· 15 citedOpen Access
Supplementary Data SD1 from Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy
2023Open Access
Figure S1 from Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy
2023Open Access
Figure S2 from Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy
2023Open Access
Figure S3 from Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy
2023Open Access
Supplementary Data SD1 from Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy
2023Open Access
Data from Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy
2023Open Access
Figure S1 from Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy
2023Open Access
Figure S4 from Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy
2023Open Access
Figure S3 from Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy
2023Open Access
Data from Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy
2023Open Access
Figure S4 from Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy
2023Open Access
Figure S2 from Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy
2023Open Access
Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy
Cancer Research Communications·2022· 14 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Indrasena Reddy Kummetha(14), Tariq M. Rana(14), Zhouting Zhu(13), Sarah Huff(13), Lingling Wang(13), Na Li(13), Christian Grimm(11), Carla Abrahamian(6), Anna Scotto Rosato(5), Franz Bracher(5), Martin Biel(5), Cheng‐Chang Chen(4), Karin Bartel(4), Christian Wahl‐Schott(3), Thomas Fröhlich(3), Veronika Kudrina(2), Eva Plesch(2), Thomas Gudermann(2), Ponsawan Netcharoensirisuk(2), Yu‐Kai Chao(2)